- 14February
-
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
MILAN, Feb. 13, 2025 /PRNewswire/ — Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round. The financing was led by a new investor, Fondazione ENEA Tech e Biomedical, with additional participation from existing investors Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F.
This significant influx of capital will empower Newronika to expand the clinical validation and commercialization of its proprietary adaptive DBS system, its innovative platform designed to deliver precision therapy aimed to improve symptom relief and reduce side effects for Parkinson’s disease patients. The funds will also facilitate the advancement of product pipelines, recruiting top-tier talent, and establishing strategic collaborations that further strengthen the company’s position at the intersection of medical device engineering and neuroscience.
Newronika’s continued momentum – evidenced by recent The Michael J. Fox Foundation grant and IDE approval, and now a substantial funding round – underscores the company’s central mission: to champion a paradigm shift in neuromodulation. Adaptive DBS represents the future of personalized brain stimulation, and Newronika remains dedicated to leading that evolution.
“We are thrilled with the strong support from both new and existing investors,” said Dr. Lorenzo Rossi, Co-Founder and CEO of Newronika. “This Series B round validates our commitment to transform the way deep brain stimulation is delivered. We aim to seamlessly integrate real-time neural data and machine learning into our DBS systems to create truly personalized therapies that surpass the capabilities of existing devices on the market.”
“With Newronika and its adaptive DBS platform, we see extraordinary potential to revolutionize the treatment of movement disorders on a global scale,” said Maria Cristina Porta, ENEA Tech e Biomedical General Manager. “Their innovative approach, capable of real-time, personalized neuromodulation, perfectly aligns with our vision of supporting disruptive medical technologies. We are excited to partner with Newronika to deliver next-generation DBS solutions to patients in need. Investing in technologies like this means caring for people’s health while creating value and driving innovation within our Country’s ecosystem.”
Davide Turco, CEO of Indaco said: “Indaco is proud to continue supporting Newronika, also through its Indaco Venture I – Lombardia Parallel Fund, in the upcoming clinical and commercial phases. We strongly believe that Newronika’s adaptive DBS system will improve the quality of life for many Parkinson’s patients.”
“This successful Series B financing round further solidifies Newronika’s strategic vision and commitment to pushing the boundaries of DBS technology to benefit patients” said Claudio Giuliano, Chairman of Newronika.
Posted on 14 Feb 2025 Newronika
